News
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma announces receipt of non-refundable upfront cash payment following the successful closing of its royalty purchase agreement with HealthCare Royalty
Heidelberg Pharma receives USD 25 million upfront cash payment from HealthCare Royalty for royalty purchase agreement. Funds to advance ADC pipeline development and extend cash runway -
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma announces progress into Cohort 6 with its proprietary ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study
Heidelberg Pharma progresses into Cohort 6 with ATAC candidate HDP-101 in Phase I/IIa multiple myeloma study, showing first objective responses and partial remissions. Amended protocol includes optimized dosing regimens -
-
-
-
COMMUNIQUÉ DE PRESSE
Heidelberg Pharma to Present First Efficacy Data on HDP-101 and Data from Proprietary ADC Technology Platform at AACR Meeting 2024
Heidelberg Pharma to present first efficacy data on HDP-101 and data from proprietary ADC technology platform at AACR Meeting 2024. Details of ATAC and ADC-based cancer therapies -
